3 February 2017 - LexaGene is pleased to announce the appointment of Mr. Daryl Rebeck as President of the Company. Mr. Rebeck is currently a director of LexaGene and has accepted this new position as President effective January 1, 2017. Mr. Rebeck was instrumental in successfully executing the reverse takeover and thereby bringing LexaGene into the public sector. Jack […] > VIEW

28 November 2016 - Lexagene is pleased to announce the appointment of Allan Fabbro as Vice-President (Corporate Development) of the Company. Mr. Fabbro has over 30 years’ experience in both the finance and mining industries. From 1984 to 1990, he headed the retail trading department at Yorkton Securities, followed by six years with Yorkton’s Natural Resources Group. After working […] > VIEW

14 October 2016 - LexaGene is pleased to announce the completion of its previously announced reverse takeover transaction (the “RTO”) pursuant to which it acquired Bionomics Diagnostics Inc. (“BDI”). The Company’s common shares will commence trading on the TSX Venture Exchange (the “TSXV”) as a Tier 2 technology issuer under the symbol “LXG” once the TSXV’s conditions for listing […] > VIEW

5 October 2016 - Company is pleased to announce the completion of its previously announced non – brokered private placement pursuant to which the Company has issued 8,400,800 common shares in the capital of the Company (the “Shares”) at a price of $0.25 per Share for aggregate gross proceeds of $2,100,200 (the “Offering”). The Offering was conducted pursuant to […] > VIEW